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MODULATION OF ESTROGEN METABOLISM
AND PREVENTION OF PATHOLOGIES
Bodhisattwa Mondal, Ph.D.
University of Nebraska, 2019
Supervisor: Eleanor G. Rogan, Ph.D.
Estrogens have been implicated in non-cancerous pathologies such as Fuchs Endothelial
Corneal Dystrophy (FECD), and accumulating evidence suggests estrogen genotoxicity leads to
initiation of multiple types of cancer among Caucasian populations. These studies were monoracial, and restoration of estrogen metabolism imbalance using naturally occurring compounds
were not definitive. Therefore, the role of estrogen metabolism in FECD, in cancer initiation among
African American (AA) populations, its modulation by environmental toxicant arsenic trioxide
(As2O3), and by antioxidants polydatin (PD) and resveratrol were explored.
In human breast epithelial non-transformed MCF10A cells, As2O3 – induced cytotoxicity
was partially ameliorated by 25 μM resveratrol. Both 25 μM resveratrol and As2O3 induced NQO1,
possibly via Nrf2 stabilization. As2O3 suppressed CYP1B1 expression whereas 25 μM resveratrol
restored it to basal levels -- rendering the As2O3 + resveratrol combination a little less effective than
As2O3 alone in lowering estrogen-DNA adduct formation. Therefore, we cannot conclude that
resveratrol co-treatment with As2O3 has any beneficial roles on estrogen metabolism, although
resveratrol might provide some chemical protection as well as the protection from As2O3cytotoxicity might stem from other cellular pathways.
PD was found to be safer than resveratrol. In MCF10A cells, PD was found to be less
efficacious than resveratrol in inducing NQO1 or repressing CYP1B1, although this difference was
abolished in human prostate epithelial non-transformed RWPE-1 cells – rendering both the
antioxidants equally effective in lowering estrogen-DNA adduct formation. This indicates PD
could be a less toxic alternative for resveratrol in chemo-preventing estrogen-induced cancer
initiation in prostate cells.
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AA women with breast cancer, and AA men at high risk for or with prostate cancer,
exhibited higher estrogen-DNA adduct ratios than the controls. This suggests loss of estrogen
metabolism balance might be instrumental in breast and prostate cancer initiation in AA
populations.
In the menadione-induced FECD model of HCEnC-21T cells, N-acetylcysteine (NAC) was
observed to ameliorate estrogen-DNA adduct formation, and this effect was sustained even in
NQO1 KO cells. Therefore, NAC can be a promising therapeutic modality for FECD where loss of
NQO1 has been reported. This needs to be replicated in animal models.
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Introduction
Estrogen Metabolism and Cancer
Cancers comprise a spectrum of multifactorial malignant disorders in the body, and the
causative factors range from diet to lifestyle to environmental pollutants. Following James and
Elizabeth Miller’s chemical carcinogenesis principles (Miller and Miller, 1981) and observing the
structural similarity between environmental carcinogens like benzene and polycyclic aromatic
hydrocarbons (PAHs) and endogenous aromatic compounds like estrogen and dopamine led to the
search for endogenous carcinogens. Although estrogens have myriad beneficial roles in the body
including breast (Brisken and O'Malley, 2010) and uterine development (Groothuis et al., 2007),
bone resorption reduction (Kameda et al., 1997), anti-atherosclerosis (Li et al., 2004) etc., they
have also been implicated in a number of diseases, including breast (Chlebowski et al., 2003) and
uterine cancer progression (Grady et al., 1995). Interestingly, studies by Bocchinfuso et al.
demonstrated tumor development in an estrogen receptor (ER) knock out transgenic mouse model
of breast cancer; and elimination of estrogen by pre-pubertal ovariectomy increased tumor-free
survival rates (1999). At the same time, studies by Russo et al. demonstrated that treatment of
immortalized but non-transformed ER-α negative breast epithelial cells MCF10F with estradiol
(E2) or 4-OHE2 led to transformation (2003), and inclusion of antiestrogens did not affect the
observed transformation (Lareef et al., 2005). Such in vitro and in vivo evidence suggests the
presence of some receptor-independent pathway of cancer initiation, and the central hypothesis of
our laboratory is that metabolism of estrogens/androgens or environmental estrogenic compounds
generates catechol quinones that can react with DNA, leading to the formation of apurinic sites,
which in turn generate mutations, and initiate oncogenic transformation (Fig. 1).
Mutagenicity of estrogen and its various metabolites has indeed been demonstrated in
animal models: E2-3,4-Q in the dorsal skin of female SENCAR mice (Chakravarti et al., 2001) and
E2 and 4-OHE2 in mammary glands of Big Blue® (BB) rats (Cavalieri et al., 2006). Numerous
epidemiological studies have documented evidence of significantly higher levels of depurinating
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estrogen-DNA adducts in high-risk groups and cancer patients [Women: breast, both in urine
(Gaikwad et al., 2009) and serum (Pruthi et al., 2012), ovarian (Zahid et al., 2014), and thyroid
(Zahid et al., 2013); Men: prostate (Markushin et al., 2006, and Yang et al., 2009), and nonHodgkin Lymphoma (Gaikwad et al., 2009)] compared to the levels in healthy controls. This
indicates estrogen-DNA adduct formation is a not an event associated with cancer promotion, but
rather with cancer initiation.
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Fig. 1. Metabolism of estrogens leading to depurination of DNA (Adapted from Cavalieri et
al., 2006).

4

Modulation of Estrogen Metabolism
Evidence suggests the imbalance of estrogen/androgen metabolism in high-risk groups and
cancer patients can stem from irregular expression patterns of one or more of the four key estrogenmetabolizing enzymes: aromatase or Cytochrome P450 19 (CYP19), Cytochrome P450 1B1
(CYP1B1) (and CYP1A1), catechol-O-methyltransferase (COMT), and NADPH Quinone Oxidase
(NQO1) (Singh et al., 2005). As shown in Fig. 1, a greater activity of aromatase and/ or CYP1B1
(or CYP1A1) leads to formation of more estrogen-DNA adducts, and hence these two are known
as activating enzymes. On the other hand, a greater activity of NQO1 and/or COMT leads to
formation of fewer estrogen-DNA adducts, and hence these two are known as protective enzymes.
Among these, NQO1 and CYP1B1 (or CYP1A1) are highly inducible. NQO1 has been shown to
be induced by the Nrf2-Keap1 signaling pathway (Lu et al., 2008). Therefore, compounds that
stabilize Nrf2 protein and promotes its nuclear translocation can lead to induction of NQO1
expression and a concomitant decrease in estrogen-DNA adduct formation (Fig. 2). On the other
hand, CYP1B1 (and CYP1A1) has been shown to be induced by the Aryl Hydrocarbon Receptor
or AhR signaling pathway (Zahid et al., 2008). Therefore, compounds like 2,3,7,8Tetrachlorodibenzo-p-dioxin or TCDD that activate AhR signaling can lead to induction of
CYP1B1 (and CYP1A1) expression and concomitant increase in estrogen-DNA adduct formation
(Fig. 2). Taken together, estrogen metabolism is subject to modulation by a variety of chemical
agents or physical forces like UV, which depending on the protecting or activating enzyme target,
can either increase or decrease the odds for breast or other cancer initiation. Under such
circumstances, studying the effects of environmental contaminants like arsenic trioxide in
modulating estrogen metabolism is important to identify populations disproportionately susceptible
to estrogen-induced breast and prostate cancer initiation. On the other hand, investigating the
efficacy of naturally occurring antioxidants like resveratrol or its precursor polydatin (PD) in
restoring a unbalanced estrogen metabolism can provide mechanistic understanding for use of new
chemopreventive approaches targeted at the breast or prostate cancer initiation step.
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Fig. 2. Environmental compounds modulating signal transduction pathways upstream of key
estrogen-metabolizing enzymes NQO1 and CYP1B1. (Adapted from He et al, 2006).
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Polymorphisms in Key Estrogen-Metabolizing Enzymes
Among the four key enzymes involved in estrogen metabolism, we observed genetic
polymorphisms in COMT and CYP1B1, affecting enzymatic stability and/or activity. A guanineto-adenine single nucleotide polymorphism (SNP) (SNP ID: rs4680) in the codon 158 of long-chain
or membrane-bound COMT (MB-COMT) or in the codon 108 of short-chain or soluble COMT (SCOMT) causes coding of methionine instead of a valine residue, and this is annotated as a
Val108/158Met substitution. This is a loss-of-function mutation, and individuals homozygous for
the polymorphic allele (COMTLL or Met/Met) have been reported to have 4 to 5-fold lower activity
of COMT compared to the same in individuals homozygous for the wild type allele (COMTHH or
Val/Val) (Porcelli et al., 2011). A lower activity of the protective enzyme COMT would cause
more estrogen-DNA adduct formation and this might lead to an increased probability of
tumorigenesis. Although almost a quarter of the Caucasian population in the US report
homozygosity for the COMTLL allele (Scanlon et al., 1979), epidemiological studies correlating
this polymorphism with heightened breast cancer risk have been somewhat inconclusive (Yim et
al., 2001).
CYP1B1 is a microsomal monooxygenase that catalyzes the oxidative activation of
exogenous procarcinogens like polyaromatic hydrocarbons (PAH) and endogenous procarcinogens
like estrogens. The literature shows several mutations for CYP1B1 gene among populations. A
cytosine-to-guanine SNP (SNP ID: rs1056836) in the codon 432 causes missense coding of valine
instead of a leucine residue. This Val432Leu is a gain-of-function mutation, and a higher 4-OHE1:
2-OHE1 ratio reflecting a higher CYP1B1 activity has been reported among homozygotes for the
variant allele (Val/Val) compared to the same in wild type carriers (Leu/Leu), and the effects were
robust enough to be seen in a small sample size of 20 (Paracchini et al., 2005). A higher activity of
the activating enzyme CYP1B1 would cause more estrogen-DNA adduct formation and this might
lead to an increased probability of tumorigenesis. On the other hand, an adenine-tocytosine/guanine SNP (SNP ID: rs1800440) in the codon 453 of CYP1B1 gene causes another
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missense mutation, leading to a threonine/serine substitution for asparagine. This Asn453Thr/Ser
mutation has been correlated with a higher catalytic activity as well as with a lower stability by
increasing its rate of degradation. This enhanced degradation of CYP1B1 has been postulated to
exert protection against carcinogenesis (McGrath et al., 2004).
Studies investigating the correlation between one gene polymorphism and risk of
carcinogenesis are sometimes inconclusive or might not have enough statistical power.
Interestingly, one study reported women simultaneously homozygous to polymorphic COMT allele
(Val108/158Met) and polymorphic CYP1B1 allele (Val432Leu) were six times more likely to have
ovarian cancer than their counterparts carrying wild type alleles for both genes (Zahid et al., 2014).
Although no similar studies have been reported for breast or other cancers, a similar polygenic
approach can be instrumental in exploring the role of genetic polymorphisms among key estrogenmetabolizing enzymes in precipitating hormonal cancers.

Racial Disparity in Cancer Etiology and Estrogen Metabolism
An important inclusion criterion in studies exploring the levels of estrogen-DNA adducts
in cancers, high risk groups, and controls was Caucasian race. In fact, the estimation of risk using
the Gayle model score only works for Caucasians. However, to the best of our knowledge, no
comparative studies on estrogen-DNA adduct formation between cancer cases and controls in
African-American (AA) or Asian populations have been reported in the literature.
The incidence of breast cancer among AA women is slightly higher compared to the same
among Caucasian women. Albeit, breast cancer in AA women represents a much aggressive form
leading to a greater mortality (Alcaraz et al., 2016), and appearance of triple negative (for ER, PR,
and HER2) breast cancer has been reported before menopause (DeSantis et al., 2016). On the other
hand, Asian women typically report lower breast cancer incidences compared to the same among
Caucasian or AA women (Parkin et al., 1992).
In the light of such similar incidences yet a somewhat different etiology leading to higher

8

mortality, exploring estrogen metabolism in AA populations can be imperative in understanding
the mechanistic basis of the racial comparisons and contrasts. To the best of our knowledge, the
present literature lacks any such studies on estrogen metabolism and carcinogenesis in AA
populations. Also, a similar polygenic approach discussed in the earlier section among Caucasian
populations can be equally useful to explain any observed anomalies in estrogen metabolism in AA
populations. Together, these might pave the way for exploring estrogen metabolism and its role in
carcinogenesis among non-Caucasian populations.

Estrogen Metabolism in Fuchs Endothelial Corneal Dystrophy (FECD)
FECD is a late onset degenerative ocular disease that affects corneal endothelium of both
eyes leading to gradual loss of vision (Friedenwald et al., 1925). Its incidence is roughly estimated
as 1 in 2000 individuals although cross-sectional studies indicate European populations to be
disproportionately affected (Zoega et al., 2006). FECD is considered a multifactorial genetic
disorder whose molecular etiology is not fully understood, resulting in a lack of chemotherapeutic
drugs. Owing to this fact, FECD is currently the leading cause of corneal transplantation surgeries
in the U.S. per year (Gain et al., 2016).
In healthy eyes, the basement membrane (Descemet’s membrane) separates corneal stroma
from aqueous humor (AH), whereas the corneal endothelial (CE) cells sitting on Descemet’s
membrane act as pumps to maintain the clarity of corneal stroma. These CE cells are postmitotically arrested, therefore acute insults that cause DNA damage and induce apoptosis might
shrink the threshold functional pool of CE cells --leading to influx of AH, corneal edema, and loss
of clarity/vision. Indeed, hallmark features of FECD pathogenesis include CE cell loss, thickening
of Descemet’s membrane, and focal outgrowths in the central cornea called guttae (Vogt, 1921)
(Fig. 3). Both central corneal guttae formation and FECD have been reported to be higher among
females (Wilson et al, 1988), and this skewed gender ratio is yet to be explained satisfactorily.
Interestingly, sex hormones have been implicated in FECD pathobiology, although the present
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literature lacks any definitive studies.
The pathology of FECD starts with the central cornea and gradually spreads peripherally
(Doutch et al., 2012). On the other hand, the central cornea receives more UV light than the
peripheral parts – thereby making exposure to UV a potential candidate to initiate FECD. UV
exposure can differentially induce different cytochrome P450 enzymes (Katiyar et al., 2000), some
of which play key roles in estrogen metabolism discussed earlier. Owing to a lack of protective
histones and a greater extent of ROS-induced lipid peroxidation in the inner mitochondrial
membrane, mitochondrial DNA (mtDNA) has been reported to be damaged more by estrogen
metabolites than genomic/ nuclear DNA (nDNA) (Thomas and Roy, 2001). Furthermore, the ROSscavenger N-acetylcysteine (NAC) has been shown to restore estrogen metabolism balance and
protect from the accumulation of genotoxic metabolites (Cavalieri and Rogan, 2016). Therefore,
exploring the role of UV exposure – estrogen metabolism axis in precipitation of CE cell
mitochondrial dysfunction and apoptosis can provide molecular insights into FECD etiology and
might potentiate the use of chemotherapeutic agents like NAC.

10

Fig. 3. FECD pathobiology schematic depicting the causative factors and key events. (Adapted
from Jurkunas et al, 2010).
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A literature survey indicates estrogen metabolism disbalance might play a role in
precipitating non-cancerous pathologies such as FECD, whereas accumulating evidence suggests
estrogen genotoxicity is an endogenous pathway for initiation of multiple types of cancer among
Caucasian populations; although the present literature lacks any correlation studies between
estrogen metabolism and cancer initiation among non-Caucasian populations. Collectively, the
disbalance in the said metabolism has been attributed to four critical enzymes, but another level of
complexity lies in the fact that some of these enzymes are subjected to modulation by naturally
occurring antioxidants or toxicants, whereas some manifest gain-of-function, loss-of-function or
even missense mutation polymorphisms. Under such circumstances, this study aims to explore the
role of estrogen metabolism in non-cancerous pathologies (FECD), in cancer initiation among nonCaucasian populations (AA), and its modulation by environmental toxicants (As2O 3) and naturally
occurring antioxidants (PD and resveratrol) – which will be discussed in the subsequent chapters.
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Chapter 1: Estrogen Metabolism and Arsenic Trioxide
Introduction
Arsenic is the 20th most abundant element in the earth’s crust, and trivalent arsenic trioxide
(As2O3) contaminates groundwater in many places, leading to arsenic poisoning or arsenicosis
(Saha et al., 1999). Arsenic and inorganic arsenic compounds have been classified as IARC Group
1 carcinogens (Straif et al., 2009), with lung, bladder, kidney and liver as the predominant targets.
At the same time, As2O3 (Trisenox or ATO) is being used as a chemotherapy drug against acute
promyelocytic leukemia (APL), where it selectively kills the leukemic cells but allows the proper
development of regular blood cells (Soignet et al., 1998). Interestingly, arsenic has long been
implicated

in

endocrine

disruption.

Target

genes

for

glucocorticoids,

androgens,

mineralocorticoids, and progestin receptors have also been reported to be regulated by inorganic
arsenic in a biphasic dose-response fashion (Bodwell et al., 2006). To address such documented
carcinogenicity and putative endocrine disruption, the U.S. Environmental Protection Agency has
set the Maximum Contaminant Level for As2O3 at 10 ppb (US EPA, 2001).
The principal pathways implicated in As 2O 3-toxicity result from reactive oxygen species
(ROS), oxidative DNA damage, and induction of apoptosis. Resveratrol, a well-known dietary
stilbene, has been shown to protect normal human bronchial epithelial cells from As2O3-toxicity by
maintaining glutathione homeostasis (Chen et al., 2015). Cardiotoxicity, a major side effect of using
As2O3 for APL, could be ameliorated in Wistar rats by resveratrol, via maintenance of a balanced
expression of the Nrf2-heme oxygenase (HO)1 pathway, and by promoting arsenic efflux from cells
(Zhang et al., 2013). Employing similar mechanisms, resveratrol has been reported to protect from
As2O3-induced nephrotoxicity in male Wistar rats (Zhang et al., 2014), and from hepatotoxicity in
Chinese Dragon-Li cats (Zhang et al., 2014). Finally, research by at least one group has
demonstrated the ability of inorganic arsenic to promote carcinogenesis via a non-estrogen receptor
(ER)-mediated pathway: chronic exposure (18 weeks) to environmentally relevant 0.5 µM arsenite
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promoted cancer cell phenotypes in human prostate epithelial stem/progenitor cells (WPE-stem)
(Tokar et al., 2010), and in its isogenic parental RWPE-1 cells (30 weeks) (Achanzar et al., 2002).
Chronic exposure (24 weeks) to low-level arsenite (500 nM) has also been reported to do the same
thing in human breast epithelial cells (MCF10A) via overexpression of aromatase (Xu et al., 2014).
To the best of our knowledge, no studies have explored any protective role of resveratrol on As2O3induced carcinogenesis via non-ER-mediated pathways.
Estrogens have been implicated in the development of a variety of cancers. Several types
of evidence suggest the role of estrogen in tumor development in an ER knock-out transgenic
mouse model of breast cancer (Bocchinfuso et al., 1999), as well as in the transformation of ERαnegative breast epithelial cells (MCF10F) (Russo et al., 2003). To explain such receptorindependent pathways for cancer initiation, it has been hypothesized that metabolism of
estrogens/androgens generates catechol quinones that can react with DNA, leading to the formation
of apurinic sites and mutations, to initiate oncogenic transformation (Cavalieri and Rogan, 2014).
In high-risk groups and cancer patients (women: breast, ovarian, and thyroid; men: prostate and
non-Hodgkin lymphoma), an imbalance in estrogen metabolism stems from irregular expression
patterns of one or more of the four key estrogen-metabolizing enzymes: CYP19 or aromatase,
CYP1B1, COMT, and NQO1 (Cavalieri and Rogan, 2014). Certain naturally occurring or synthetic
compounds can alter the expression of some of these enzymes; e.g. TCDD can induce CYP1B1,
whereas resveratrol antagonizes this effect. At the same time, resveratrol can induce NQO1 (Zahid
et al., 2008). Pre-incubation with 25 μM resveratrol for 48 h significantly lowered the production
of estrogen-DNA adduct formation in ERα-negative human breast epithelial MCF10F cells (Zahid
et al., 2008). Therefore, in this study, the effects of As 2O 3 on the expression levels of key estrogenmetabolizing enzymes (NQO1 and CYP1B1), and on the signaling molecule Nrf2, were studied in
the presence or absence of 25 μM resveratrol in immortalized but non-transformed ERα-negative
human breast epithelial cells MCF10A, MCF10F and MCF12F.
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Methodology
Cell lines and cell culture: For this study, the following immortalized but non-transformed ERαnegative human breast epithelial cell lines were acquired from ATCC (Rockville, MD):
1. MCF10A,
2. MCF10F and
3. MCF12F
These cells were cultured in DMEM and Ham’s F12 growth medium (1:1; Invitrogen)
supplemented with 5% fetal bovine serum (FBS), 20 ng/ml epidermal growth factor, 0.01 mg/ml
insulin, 500 ng/ml hydrocortisone, 10 ng/ml cholera toxin and 100 μg/ml penicillin/streptomycin
mixture. For assay purposes, estrogen-free medium was prepared using phenol red indicator-free
DME/F12 medium (Invitrogen) and charcoal-stripped FBS and was supplemented as described
above. Cells were grown or subjected to assays in flasks (25-150 mm2), 6 or 96-well plates in a
humidified atmosphere containing 5% CO2 at 37ºC.
Cytotoxicity: Upon exposure to varying concentrations of As 2O3 and/or resveratrol, cell viability
was determined by the MTT assay, which reflects the reduction of MTT to purple-colored formazan
by dehydrogenase enzymes present in viable cells. Cells were seeded in a 96-well plate (seeding
density: MCF10A 3000 cells per well, MCF12F 5000 cells per well) in estrogen- and phenol red
indicator-free media and treated with 0.5 – 50 μM total concentration of As2O3 (Purity > 99.5%;
Sigma-Aldrich, St. Louis, MO), 12.5 – 200 μM total concentration of resveratrol (Purity ≥ 98%;
Cayman Chemical, Ann Arbor, MI), or 0.5 – 50 μM total concentration of As2O3 + 25 μM
resveratrol for 2 time points (48 and 72 h). Finally, MTT (Calbiochem, San Diego, CA) was used
to assess cell viability and corresponding IC50 values were compared.
Protein Expression Studies: Expression levels of the key estrogen-metabolizing enzymes NQO1,
CYP1B1, and CYP1A1, and of cell signaling protein Nrf2 were studied under different treatment
regimens. Cells were seeded in a 6-well plate (seeding density: MCF10A and MCF10F 0.8X10 6
cells per well, MCF12F 1X10 6 cells per well) in estrogen- and phenol red indicator-free media, and
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treated with 0.5 – 5 μM concentration of As2O3 ± 25 μM resveratrol for 48 h. Following cell lysis
with RIPA buffer containing 50 mM Tris-HCl pH 7.5, 1 mM EDTA pH 8.0, 150 mM NaCl, 10 mM
MgCl2, 1% NP-40 and 0.005 µg/ml protease inhibitor cocktail (Roche Diagnostics, Basel,
Switzerland), total protein was estimated by the Bradford assay, and 10-50 μg of total protein were
resolved on a 7.5% polyacrylamide gel and transferred to PVDF membranes. The membranes were
probed with anti-NQO1, anti-Nrf2 (Abcam, Cambridge, MA), anti-CYP1B1 (LSBio, Seattle, WA),
anti-CYP1A1 (Sigma-Aldrich, St. Louis, MO) or anti-β-actin (Santa Cruz, Dallas, TX) primary
antibodies overnight at 4°C and secondary antibodies for 1 h at room temperature. Detection was
performed with ECL Western Blotting Detection Reagents (GE Healthcare/Amersham, Little
Chalfont, UK). Densitometric analyses of Western blots were performed using Bio-Rad’s Image
Lab™ software 4.1. Normalization was done with β-actin expression, and both the treatment and
western blotting were performed three times to achieve statistical significance.
Analysis of Estrogen-Metabolism: MCF10A cells were seeded in T75 flasks at 0.25X106 cells
per T75 flask with 5 flasks per treatment. Following attachment, cells were pre-treated with
estrogen- and phenol red indicator-free media for 48 hrs, and treatment was given with 5 μM As2O3
or 25 μM resveratrol or both for 48hrs. Finally, treated cells were incubated for 24 hrs with fresh
medium containing DMSO control, 10 μM 4-catechol estrogen or 25 μM estradiol to study the
biological effect of As2O3 and resveratrol on estrogen metabolism. The collected media was stored
in -80° freezer or was partially purified by using SPE phenyl cartridges, concentrated with a
SpeedVac and lyophilized (Gaikwad et al., 2008). The lyophilized eluates were reconstituted in 50
µl of methanol-water solution (1:1) and passed through a 5000 m.w. cut-off filter before 10 µl of
each sample was subjected to ultraperformance liquid chromatography/tandem mass spectrometry
(UPLC-MS/MS) analysis, carried out with a Waters Acquity UPLC system connected with a high
performance Quattro Micro triple quadrupole mass spectrometer as previously described (Gaikwad
et al., 2008). Resulting data were processed by using QuanLynx software (Waters) to quantify: 1.
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Depurinating estrogen-DNA adducts, 4-OHE1(E2)-1-N3Ade, 4-OHE1(E2)-1-N7Gua, and 2OHE1(E2)-6-N3Ade; 2. 4- and 2-catechol estrogen metabolites 4-OHE1(E2) and 2-OHE1(E2); 3. 4and 2-catechol estrogen methoxy conjugates 4-OCH3E1(E2) and 2-OCH3E1(E2); and 4. 4-catechol
estrogen quinone conjugates 4-OHE1(E2)-2-SG, 4-OHE1(E2)-2-Cys, and 4-OHE1(E2)-2-NAcCys.
Quantification of the estrogen compounds was provided by comparison to standard response curves
for each compound. The precision of these analyses is provided by the limit of detection and
coefficient of variation for the UPLC-MS/MS method, which were presented earlier (Gaikwad et
al., 2008). All the study samples were analyzed in triplicates or duplicates.
Among the standards, estrogen-3,4-quinone conjugates were synthesized by the reactions
of estrogen quinones with reduced cysteine, N-acetylcysteine, or glutathione (Cao et al., 1998).
Estrogen–DNA adducts were synthesized by following methods reported in the literature (Stack et
al., 1996, Li et al., 2004, Zahid et al., 2006). All other analytical standards were purchased from
Steraloids (Newport, RI).
Statistical Analysis: To determine whether the differences observed were statistically significant
or not, a 2-sample t-test was performed. Alpha was set at 0.05 for all statistical tests and data with
p < 0.05 were considered to be significantly different.
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Results and Discussion
25 μM Resveratrol Protected from the Cytotoxicity of As2O3: As2O3 exhibited cytotoxicity at
both 48 and 72 hrs, with an IC50 at 1.45 μM for 48 hr treatment (Fig. 4.A), which is an
environmentally significant exposure. However, the presence of resveratrol, which also has some
cytotoxicity (Fig. 4.B) at 25 μM, reduced this cytotoxicity by shifting the survival curves to the
right. The IC50 for combined 48 hr As2O3 and resveratrol treatment was 28.69 μM. The rightward
shift in survival curve was lesser for 72 hr treatment compared to that for 48 hr treatment (Fig. 4.C).
This indicates that the rescue effect from resveratrol was more pronounced at 48 hr.
Both 25 μM Resveratrol and As2O3 Induced NQO1 and Nrf2 Expressions: As2O3, with or
without 25 μM resveratrol, induced the enzyme NQO1 in a dose-dependent manner, but no additive
or synergistic effects were observed (Figs. 5.A and 5.B). Resveratrol has been shown to act via the
signaling molecule Nrf2, and NQO1 has been reported as a downstream gene of Nrf2 (Ungvari et
al., 2010). This prompted us to study the effect of As 2O3 on the expression level of Nrf2. As2O3, in
both the presence and absence of 25 μM resveratrol, increased Nrf2 protein levels in a dosedependent fashion, but again no additive or synergistic effects were observed (Figs. 5.C and 5.D).
Our finding is in accordance with a study in mouse hepatoma cell line hepa1c1c7, in which arsenic
was shown to increase Nrf2 protein levels in a dose-dependent fashion, leading to a robust induction
of NQO1 (He et al., 2006). Furthermore, in MCF10A cells, the degree of increase in Nrf2 protein
levels was much greater for Nrf2 compared to that for NQO1, but this may stem from the fact that
resting cells have a very low-level basal expression of Nrf2 (t1/2=10-20 mins) (Itoh et al., 2003).
Similar disproportionate inductions of NQO1 and Nrf2 by As2O3 has been reported in male
Kunming mouse testis in both the presence and absence of anti-oxidants such as lutein (Li et al.,
2016).
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Fig. 4. Viability of MCF10A cells treated with As2O3 with and without resveratrol. (A) As 2O3
alone. (B) Resveratrol alone. (C) As2O3 + 25 μM Resveratrol. Data are presented as mean ±
standard error of the mean cell survival (% of control) from six independent experiments (n=6)
(Mondal et al., 2018).
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Fig. 5. Induction of NQO1 (A & B) and Nrf2 (C & D) in MCF10A cells by As2O3 with and
without resveratrol. (A) and (C) Representative images. (B) and (D) Quantitative data. Data
are presented as mean ± standard error of the mean protein expression (% of control) from three
independent experiments (n=3), X= Mean of two experiments. A † indicates significant difference
(p<0.05) between As2O 3 treatment groups and control whereas an * indicates significant difference
(p<0.05) between As2O3 treatment groups and control in the resveratrol group (Mondal et al.,
2018).
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As2O3 Suppressed CYP1B1 Expression whereas 25 μM Resveratrol Rescued It: CYP1B1 is
another key estrogen-metabolizing enzyme that is overexpressed in a variety of cancers, including
breast, and is subject to regulation through both hormonal and a putative AhR pathway; the latter
can be modulated by resveratrol (Spink et al., 1998). Previous studies on the male C57Bl/6 mouse
heart have reported that 12.5 mg/kg As(III) induces CYP1B1 mRNA levels by 150% (AnwarMohamed et al., 2012). We observed, however, that As2O3 treatment (0.5 – 5 μM) of human breast
epithelial MCF10A cells caused repression of CYP1B1 protein in a dose-dependent manner.
Resveratrol was earlier shown to downregulate TCDD-induced CYP1B1 expression in MCF10F
cells (Lu et al., 2008). Interestingly, addition of 25 μM resveratrol rescued As2O3-suppressed
CYP1B1 expression and kept it at a nearly constant level (Figs. 6.A and 6.B). To confirm this
interesting observation, expression of CYP1B1 enzyme was further studied simultaneously in three
different non-transformed cell lines derived from human breast epithelia, namely MCF10A,
MCF10F and MCF12F cells. In this study, the cells were also treated with a higher dose of 7.5 µM
As2O3. The repressive effect of As2O 3 on CYP1B1 expression was less pronounced in MCF10F
cells -- leaving little room for resveratrol to exert any rescue effect (Figs. 7.C and 7.D).
Furthermore, such repressive effect of As 2O3 on CYP1B1 expression was altogether absent in
MCF12F cells (Figs. 7.E and 7.F). Collectively, these results suggest different degrees of
modulatory effects of As2O3.
One possibility is the differential cytotoxicity of As 2O3, as we have observed between
MCF10A and MCF12F cells (IC50 value for MCF10A was 1.45 µM for 48 hr treatment, whereas
the same for MCF12F was 11.65 µM; Fig. 4.A vs. Fig. 8). As2O 3 is not considered a ligand for
AhR; therefore, the observed effects of As 2O3 might be mediated through a hormonal pathway.
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Fig. 6. Repression of CYP1B1 in MCF10A cells by As2O3 with and without resveratrol. (A)
Representative image. (B) Quantitative data. Data are presented as mean ± standard error of the
mean protein expression (% of control) from three independent experiments (n=3), X= Mean of
two experiments. A † indicates significant difference (p<0.05) between As2O3 treatment groups and
control whereas an * indicates significant difference (p<0.05) between one particular As 2O3
treatment with the inclusion or exclusion of resveratrol (Mondal et al., 2018).
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error of the mean cell survival (% of control) from six independent experiments (n=6) (Mondal et
al., 2018).

24

In conclusion, in the present study involving non-transformed breast epithelial MCF10A
cells, 25 μM resveratrol was shown to ameliorate As2O3-induced cytotoxicity; with the beneficial
effect being more prominent after 48 hr treatment. As expected, both As2O3 and resveratrol induced
the expression of the catechol quinone-quenching enzyme NQO1, possibly via stabilizing the
signaling protein Nrf2. Collectively, these results suggest that 25 μM resveratrol has the ability to
modulate the effects of As2O 3 on the expression of estrogen-metabolizing enzymes in MCF10A
cells.
Next, expression of key estrogen-metabolizing enzymes was studied from metabolic assay
experiments in MCF10A cells in the presence of 5 µM As2O3 and/ or 25 µM resveratrol. When cells
were grown for 48 hrs, the effects of As2O3 and/ or resveratrol on the expression of key estrogenmetabolizing enzymes corroborated our earlier observations. Briefly, both As2O3 and resveratrol
induced NQO1, with the former showing a stronger induction. This effect was also preserved when
cells were grown for another 24 hrs without As2O3 or resveratrol (Fig. 9). As2O3 repressed CYP1B1
whereas addition of resveratrol rescued it to some extent. However, this effect was not observed
when cells were grown for another 24 hrs without As 2O3 or resveratrol (Fig. 10). CYP1A1
expression patterns roughly followed the same as for CYP1B1, but to much lesser extents (Fig. 11).
The incubation with substrates E2 or 4-OHE2 for the final 24 hrs, however, yielded some interesting
observations. Briefly, 4-OHE2 alone repressed CYP1B1 expression by 15% (Fig. 10). As CYP1B1
activity generates 4-OHE2, this might be a defense mechanism employed by cells to handle surplus
exogenous 4-OHE2. E2 alone induced CYP1A1 expression by ~50% (Fig. 11). As E2 is a substrate
for CYP1A1, this might be a mechanism employed by cells to handle surplus exogenous E 2.
However, this might lead to greater activation of the 2-adduct formation pathway. Finally, 4-OHE2
alone repressed NQO1 expression by 30% (Fig. 9). As NQO1 activity enables cells to prevent
adduct formation from 4-OHE2, this repression might hamper cells’ ability to handle surplus
exogenous 4-OHE2. However, presence of resveratrol might aid cells in such scenarios.
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Fig. 9. Expression of NQO1 in MCF10A cells subjected to 48 hr treatment with 5 µM As 2O3
and/or 25 µM resveratrol (X), 48 hr treatment with 5 µM As2O3 and/or 25 µM resveratrol
followed by 24 hr post-treatment growth without any As2O3 or resveratrol (-), 48 hr treatment
with 5 µM As 2O3 and/or 25 µM resveratrol followed by 24 hr post-treatment with 25 µM E2
(E2), or 48 hr treatment with 5 µM As 2O3 and/or 25 µM resveratrol followed by 24 hr posttreatment with 10 µM 4-OHE2 (4-OHE2). Data are presented as mean protein expression (% of
control) from two independent experiments (n=2).
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Fig. 10. Expression of CYP1B1 in MCF10A cells subjected 48 hr treatment with 5 µM As2O3
and/or 25 µM resveratrol (X), 48 hr treatment with 5 µM As2O3 and/or 25 µM resveratrol
followed by 24 hr post-treatment growth without any As2O3 or resveratrol (-), 48 hr treatment
with 5 µM As 2O3 and/or 25 µM resveratrol followed by 24 hr post-treatment with 25 µM E2
(E2), or 48 hr treatment with 5 µM As 2O3 and/or 25 µM resveratrol followed by 24 hr posttreatment with 10 µM 4-OHE2 (4-OHE2). Data are presented as mean protein expression (% of
control) from two independent experiments (n=2).
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Fig. 11. Expression of CYP1A1 in MCF10A cells subjected to 48 hr treatment with 5 µM As2O3
and/or 25 µM resveratrol (X), 48 hr treatment with 5 µM As2O3 and/or 25 µM resveratrol
followed by 24 hr post-treatment growth without any As2O3 or resveratrol (-), 48 hr treatment
with 5 µM As 2O3 and/or 25 µM resveratrol followed by 24 hr post-treatment with 25 µM E2
(E2), or 48 hr treatment with 5 µM As 2O3 and/or 25 µM resveratrol followed by 24 hr posttreatment with 10 µM 4-OHE2 (4-OHE2). Data are presented as mean protein expression (% of
control) from two independent experiments (n=2).
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Finally, the levels of 20 estrogen metabolites including catechol estrogens, estrogen
conjugates and DNA-adducts from MCF10A cells subjected to metabolic assay were analyzed.
Both As2O3 and resveratrol, either singly or in combination, were observed to lower adduct
formation – which might stem from their inducing effects on NQO1. However, some degree of
activation is observed with the As2O3 + resveratrol combination which might stem from the rescue
effect of resveratrol rendering As 2O3 alone a better repressor for both CYP1B1 and CYP1A1 than
that by the As2O3 + resveratrol combination (Fig. 12). Supporting evidence comes from the fact
that increased catechol formation was observed with As2O3 treatment, either singly or in
combination with resveratrol – which is again indicative of induced NQO1. However, as As 2O3
represses both CYP1B1 and CYP1A1 more than the As2O3 + resveratrol combination, less catechol
formation from E2 was observed with As2O3 alone compared to the combination (Fig. 13). The
surplus catechols, generated with As2O3 treatment, either singly or in combination with resveratrol,
might lead to greater production of methoxy conjugates (Fig. 14), quinones and then quinone
conjugates (Fig. 15).
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Fig. 12. Depurinating adduct formation in MCF10A cells subjected to 48 hr treatment with 5
µM As2O3 and/or 25 µM resveratrol followed by 24 hr post-treatment with 25 µM E2 (A), or
48 hr treatment with 5 µM As2O3 and/or 25 µM resveratrol followed by 24 hr post-treatment
with 10 µM 4-OHE2 (B). Data are presented as mean ± standard error of the mean adduct
concentrations from three independent experiments (n=3).
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Fig. 13. Occurrence of catechols in MCF10A cells subjected to 48 hr treatment with 5 µM
As2O3 and/or 25 µM resveratrol followed by 24 hr post-treatment with 25 µM E2 (A), or 48 hr
treatment with 5 µM As2O3 and/or 25 µM resveratrol followed by 24 hr post-treatment with
10 µM 4-OHE2 (B). Data are presented as mean ± standard error of the mean catechol
concentrations from three independent experiments (n=3).
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Fig. 14. 4-Methoxy conjugate formation in MCF10A cells subjected to 48 hr treatment with 5
µM As2O3 and/or 25 µM resveratrol followed by 24 hr post-treatment with 25 µM E2 (A), or
48 hr treatment with 5 µM As2O3 and/or 25 µM resveratrol followed by 24 hr post-treatment
with 10 µM 4-OHE2 (B). Data are presented as mean ± standard error of the mean methoxy
conjugate concentrations from three independent experiments (n=3).
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Fig. 15. Estrogen-3,4-Quinone conjugate formation in MCF10A cells subjected to 48 hr
treatment with 5 µM As2O3 and/or 25 µM resveratrol followed by 24 hr post-treatment with
25 µM E2 (A), or 48 hr treatment with 5 µM As2O3 and/or 25 µM resveratrol followed by 24
hr post-treatment with 10 µM 4-OHE2 (B). Data are presented as mean ± standard error of the
mean 3,4-Quinone conjugate concentrations from three independent experiments (n=3).
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Collectively, the oxidative insult of cells by As2O3 did prompt cells to activate their first
line of defense, NQO1, which showed functional efficacy by lowering adduct formation and
increasing catechol and conjugate formation. Interestingly, resveratrol at 25 µM, by its rescuing
effects on CYP1B1 and CYP1A1, rendered the As 2O3 + resveratrol combination little less effective
than As2O3 alone in lowering estrogen-DNA adduct formation. Based on these studies, we cannot
conclude resveratrol co-treatment with As 2O 3 has any beneficial roles on estrogen metabolism.
However, resveratrol might be beneficial owing to its chemical properties as well as the protection
from As2O3-cytotoxicity might stem from other cellular pathways. E2 and 4-OHE2 largely affected
the expression of key estrogen-metabolizing enzymes in ways that might aid cells to restore the
balance in estrogen metabolism. One striking observation was the repression of NQO1 by 4-OHE2
(instead of induction), which might move the equilibrium of estrogen metabolism further away and
might contribute to cellular carcinogenesis in response to 4-OHE2 exposure. However, this needs
further study in multiple cell lines where imbalance in estrogen metabolism has been shown to
initiate carcinogenesis.
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Chapter 2: Estrogen Metabolism and Protective Antioxidants
Introduction
The imbalance of estrogen/androgen metabolism in high-risk groups and cancer patients
stems from irregular expression patterns of one or more of the 4 key estrogen-metabolizing
enzymes: CYP19 or aromatase, CYP1B1, COMT, and NQO1 (Singh et al., 2005). Certain naturally
occurring or man-made compounds have the ability to induce or repress the expression of some of
these key estrogen-metabolizing enzymes; e.g. TCDD, a potent environmental carcinogen can
induce CYP1B1, whereas resveratrol antagonizes this effect. At the same time resveratrol can
induce NQO1 independently (Lu et al., 2008). Our laboratory has shown that pre-incubation with
resveratrol significantly lowers the production of estrogen-DNA adduct formation in MCF10F cells
(Zahid et al., 2008). Using a cocktail of antioxidants like resveratrol and N-acetylcysteine, further
such reduction was observed (Zahid et al., 2011). However, the limited bioavailability of
resveratrol led to a search for more tolerable and efficacious antioxidants.
Resveratrol is the most well-known stilbene, but studies on European populations have
found PD to be the most abundant dietary stilbene (Zamora-Ros et al., 2008). PD or Piceid is
extensively used in Chinese traditional medicine and is isolated from the roots of Japanese
knotweed Polygonum cuspidatum (Fig. 16.A). It is also found in a variety of natural products such
as grape juice and red wine, bark of Picea sitchensis, peanuts, hop cones, hop pellets, cocoa and
chocolate products etc. It serves as a naturally-occurring precursor of resveratrol (Fig. 16.B), and
the hydrolysis takes place within the intestinal lumen, enterocytes, and hepatocytes (Henry-Vitrac
et al., 2006). However, there are 3 main differences: PD is more water-soluble than resveratrol,
resveratrol uptake happens via passive diffusion whereas PD is via carrier-mediated active transport
(Neves et al., 2012), and PD is more resistant to enzymatic oxidation than resveratrol. All these
facts indicate that PD may lead to increased bioavailability of resveratrol in serum. However, this
needs experimental proof.
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Fig. 16. (A) Japanese knotweed Polygonum cuspidatum, the most common natural source of
PD. (B) Hydrolysis of PD yields resveratrol (Adapted from Henry-Vitrac et al., 2006).
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Since the 1990’s, several studies have been carried out to explore the biological functions
of PD. PD has been shown to have anti-inflammatory roles, which may stem from a reduction in
pro-inflammatory cytokine IL-17 production (in a dose-dependent fashion) (Lanzilli et al., 2012),
or from inhibition of pro-inflammatory NF-κB signaling (Ji et al., 2012). These anti-inflammatory
effects enable PD to exert protective functions on several targets: pre-administration of PD for 5
continuous days reversed CCl4-induced acute liver injury in mice (Zhang et al., 2012); and learning
and memory functions improved in mice by neuro-protection (Li et al., 2012) etc. Several lines of
studies have documented anti-tumorigenic effects of PD. It inhibited proliferation, induced S phase
cell cycle arrest; and apoptosis of A549 and NCI-H1975 lung cancer cells (Zhang et al., 2014). PD,
alone, or in a synergistic combination of a 3:1 molar ratio with resveratrol, arrested the cell cycle,
and induced differentiation and apoptosis of Caco-2 human colorectal cancer cells (De Maria et al.,
2013). Both resveratrol and PD inhibited proliferative growth in mouse myoblast cells via estrogen
receptor β and induction of mitochondrial manganese-dependent superoxide dismutase (MnSOD)
(Robb et al., 2014). However, its effect in carcinogenesis via estrogen metabolism regulation is yet
to be explored.
Clearly, PD has chemical and physiological advantages over resveratrol, and this makes it
a very suitable candidate for studying its effect on regulating estrogen metabolism and the net
effects on carcinogenesis. This study aims to investigate this not only for PD alone, but also its
combination with resveratrol, including the predicted synergistic combination; and tease out the
most effective compound or combination to prevent carcinogenesis by perturbing the balance in
estrogen metabolism.
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Methodology
Cell lines and cell culture: For this study, the following cell lines were acquired from ATCC
(Rockville, MD):
1. MCF10A (immortalized but non-transformed human breast epithelial),
2. RWPE-1 (immortalized but non-transformed human prostate epithelial)
MCF10A cells were cultured and subjected to assays as described in Chapter 2. RWPE-1 cells were
cultured in RPMI-1640 growth medium (Invitrogen) supplemented with 10% fetal bovine serum
(FBS) and 100 μg/ml penicillin/streptomycin mixture. For assay purposes, estrogen-free medium
was prepared using phenol red indicator-free RPMI-1640 medium (Invitrogen) and charcoalstripped FBS and was supplemented as described above. Cells were grown or subjected to assays
in flasks (25-150 mm2), and 6- or 96-well plates in a humidified atmosphere containing 5% CO 2 at
37ºC.
Cytotoxicity: To carry out a systematic study of the effect of PD and resveratrol, whole cell
cytotoxicity was studied in the model cells MCF10A and RWPE-1. Following pre-treatment with
estrogen and phenol red indicator-free medium for 48 hrs, 3000 MCF10A cells or 10,000 RWPE1 cells were seeded per well in a 96-well plate and treated with 12.5 – 200 μM total concentration
of compound for 3 time points (24, 48, and 72 hrs). Finally, MTT was used to assess cell viability.
Protein Expression Studies: Expression levels of the key estrogen-metabolizing enzymes NQO1,
CYP1B1, and CYP1A1 were studied under different treatment regimens. As earlier, cells were pretreated with estrogen and phenol red indicator-free medium for 48 hrs, and 0.8X106 MCF10A cells
or 1.5X106 RWPE-1 cells were seeded per well in a 6-well plate for treatment with 12.5 – 200 μM
total concentration of antioxidant compound(s) for 2 time points (48 and 72 hrs). Following cell
lysis with RIPA buffer, total protein was estimated by the Bradford Assay, and 10-50 μg of total
protein were analyzed for NQO1, CYP1B1, and CYP1A1 expression by western blotting.
Densitometric analyses of Western blots were performed using Bio-Rad’s Image Lab™ software
4.1. Normalization was done with β-actin expression, and both the treatment and western blotting
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were performed three times to achieve statistical significance.
Analysis of Estrogen-Metabolism: Both MCF10A and RWPE-1 cells were seeded in T75 flasks
(seeding density: MCF10A 0.25X106 cells per T75 flask, RWPE-1 0.5X106 cells per T75 flask; 5
flasks per treatment). Following attachment, cells were pre-treated with estrogen- and phenol red
indicator-free media for 48 hrs, and treatment was given with 25 μM resveratrol or 25 μM PD for
48 hrs. Finally, treated cells were incubated for 24 hrs with fresh medium containing DMSO
control, 10 μM 4-OHE2 or 10 μM 4-OHE2 + antioxidant compounds (same concentration used in
48 hr treatments) to study the biological effect of antioxidant compounds on estrogen metabolism.
The collected media was analyzed by UPLC-MS/MS as described in the previous chapter for: 1.
Depurinating estrogen-DNA adducts, 4-OHE1(E2)-1-N3Ade and 4-OHE1(E2)-1-N7Gua, 2. 4catechol estrogen metabolites 4-OHE1(E2), 3. 4-catechol estrogen methoxy conjugates 4OCH3E1(E2), and 4. 4-catechol estrogen quinone conjugates 4-OHE1(E2)-2-SG, 4-OHE1(E2)-2-Cys,
and 4-OHE1(E2)-2-NAcCys.
Statistical Analysis: To determine whether the differences observed were statistically significant
or not, a 2-sample t-test was performed. Alpha was set at 0.05 for all statistical tests and data with
p < 0.05 were considered to be significantly different.
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Results and Discussion
PD Is Safer than Resveratrol: In MCF10A cells subjected to 48 hr treatment, PD had an IC50 of
approx. 200 µM whereas the same for resveratrol was approx. 50 µM. An approx. 4 times higher
IC50 for PD than that for resveratrol for 48 hr treatment indicates PD is over-all safer compared to
resveratrol (Fig. 17). RWPE-1 cells showed viability patterns similar to MCF10A cells when
treated with resveratrol or PD. However, they seem more tolerant than MCF10A cells for either of
the antioxidants (Fig. 18).
Resveratrol Induced NQO1 more than PD: In MCF10A cells, almost all treatments (except very
high doses of resveratrol) for both compounds induced NQO1 expression; and maximal induction
was observed at 48 hr treatment for both compounds. However, resveratrol showed maximal
induction at lower doses (12.5-25 µM), whereas PD increased the induction up to the highest dose
studied (200 µM) (Fig. 19).
Resveratrol Repressed CYP1B1 more than PD: On the other hand, in MCF10A cells, both
resveratrol and PD repressed CYP1B1 expression, but the degree of repression was much higher
for resveratrol than for PD. Resveratrol almost silenced the expression of CYP1B1 at 50 µM,
whereas PD lowered it to approx. 40% even at 200 µM (Fig. 20).
Taken together, in MCF10A cells, PD was found to be safer than resveratrol, but also less
efficacious in inducing the key estrogen-metabolizing enzyme NQO1 and repressing another key
estrogen-metabolizing enzyme, CYP1B1.
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Fig. 17. Viability of MCF10A cells treated with (A) Resveratrol. (B) Polydatin. Data are
presented as mean ± standard error of the mean cell survival (% of control) from six independent
experiments (n=6).
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Fig. 18. Viability of RWPE-1 cells treated with (A) Resveratrol. (B) Polydatin. Data are
presented as mean ± standard error of the mean cell survival (% of control) from six independent
experiments (n=6).
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Fig. 19. NQO1 induction in MCF10A cells treated with resveratrol (A & B) or PD (C & D).
(A) and (C) Representative images. (B) and (D) Quantitative data. Data are presented as mean
± standard error of the mean protein expression (% of control) from three independent experiments
(n=3).
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Fig. 20. CYP1B1 repression in MCF10A cells treated with resveratrol (A & B) or PD (C &
D). (A) and (C) Representative images. (B) and (D) Quantitative data. Data are presented as
mean ± standard error of the mean protein expression (% of control) from three independent
experiments (n=3).
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Next, expression of key estrogen-metabolizing enzymes was studied in metabolic assay
experiments in RWPE-1 cells in the presence of 25 µM resveratrol or PD. When cells were grown
for the final 24 hrs without any 4-catechol estrogen, the effects of resveratrol or PD on the
expression of key estrogen-metabolizing enzymes in RWPE-1 cells somewhat corroborated our
earlier observations in MCF10A cells. Briefly, both resveratrol and PD induced NQO1 in RWPE1 cells, and they were almost equally effective inducers. However, when cells were grown in the
presence of 4-OHE2 ± antioxidants, PD showed a stronger induction than resveratrol (Fig. 21).
Unlike in MCF10A cells, in RWPE-1 cells, PD showed greater repression of CYP1B1 than
resveratrol (Fig. 22). On the other hand, resveratrol showed greater induction of CYP1A1 than PD
(Fig. 23). However, when cells were grown in the presence of 4-OHE2 + antioxidant, PD exhibited
marked induction on the expression of both CYP1B1 and CYP1A1 (Figs. 22 and 23).
As observed in MCF10A cells, the incubation with 4-OHE2 alone or with 4-OHE2 +
antioxidant for the final 24 hrs yielded some interesting observations. Briefly, 4-OHE2 alone
repressed CYP1B1 expression by 30% (Fig. 22). As CYP1B1 activity generates 4-OHE2, this might
be a defense mechanism employed by cells to handle surplus exogenous 4-OHE2. On the other
hand, 4-OHE2 alone induced NQO1 expression by ~75% (Fig. 21). As NQO1 activity enable cells
to neutralize quinones generated from 4-OHE2, this might be another defense mechanism employed
by cells to handle surplus exogenous 4-OHE2.
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Fig. 21. Expression of NQO1 in RWPE-1 cells subjected to 48 hr treatment with 25 µM
resveratrol or 25 µM PD followed by 24 hr post-treatment growth without any PD or
resveratrol (-), 48 hr treatment with 25 µM resveratrol or 25 µM PD followed by 24 hr posttreatment with 10 µM 4-OHE2 (4-OHE2), or 48 hr treatment with 25 µM resveratrol or 25
µM PD followed by 24 hr post-treatment with 10 µM 4-OHE2 + 25 µM antioxidants (4-OHE2
+ 25 µM R/ PD). Data are presented as mean protein expression (% of control) from two
independent experiments (n=2).
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Fig. 22. Expression of CYP1B1 in RWPE-1 cells subjected to 48 hr treatment with 25 µM
resveratrol or 25 µM PD followed by 24 hr post-treatment growth without any PD or
resveratrol (-), 48 hr treatment with 25 µM resveratrol or 25 µM PD followed by 24 hr posttreatment with 10 µM 4-OHE2 (4-OHE2), or 48 hr treatment with 25 µM resveratrol or 25
µM PD followed by 24 hr post-treatment with 10 µM 4-OHE2 + 25 µM antioxidants (4-OHE2
+ 25 µM R/ PD). Data are presented as mean protein expression (% of control) from two
independent experiments (n=2).
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Fig. 23. Expression of CYP1A1 in RWPE-1 cells subjected to 48 hr treatment with 25 µM
resveratrol or 25 µM PD followed by 24 hr post-treatment growth without any PD or
resveratrol (-), 48 hr treatment with 25 µM resveratrol or 25 µM PD followed by 24 hr posttreatment with 10 µM 4-OHE2 (4-OHE2), or 48 hr treatment with 25 µM resveratrol or 25
µM PD followed by 24 hr post-treatment with 10 µM 4-OHE2 + 25 µM antioxidants (4-OHE2
+ 25 µM R/ PD). Data are presented as mean protein expression (% of control) from two
independent experiments (n=2).
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Finally, the levels of 14 estrogen metabolites including catechol estrogens, estrogen
conjugates and DNA-adducts from RWPE-1 cells subjected to metabolic assay were analyzed.
More adduct formation was observed in the presence of 4-OHE2. Antioxidants, by inducing NQO1,
lowered adduct formation, with PD being more effective than resveratrol. More such protection
was observed when cells were grown in the presence of 4-OHE2 + antioxidants – which might stem
from biological + chemical inhibition (Fig. 24). As observed in MCF10A cells, the supporting
evidence in RWPE-1 cells also comes from the fact that increased catechol formation was
concomitant with inhibition of adduct formation by antioxidant pre-treatment (Fig. 25). The surplus
catechols, generated by antioxidant pre-treatment or treatment, might drive the greater production
of methoxy conjugates (Fig. 26), quinones and then quinone conjugates (Fig. 27).
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Fig. 24. Depurinating adduct formation in RWPE-1 cells subjected to 48 hr treatment with
25 µM resveratrol or 25 µM PD followed by 24 hr post-treatment growth without any PD or
resveratrol (-), 48 hr treatment with 25 µM resveratrol or 25 µM PD followed by 24 hr posttreatment with 10 µM 4-OHE2 (4-OHE2), or 48 hr treatment with 25 µM resveratrol or 25
µM PD followed by 24 hr post-treatment with 10 µM 4-OHE2 + 25 µM antioxidants (4-OHE2
+ 25 µM R/ PD). Data are presented as mean adduct (4-OHE1/2-1-N7Gua + 4-OHE1/2-1-N3Ade)
concentrations from two independent experiments (n=2).
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Fig. 25. Occurrence of catechols in RWPE-1 cells subjected to 48 hr treatment with 25 µM
resveratrol or 25 µM PD followed by 24 hr post-treatment growth without any PD or
resveratrol (-), 48 hr treatment with 25 µM resveratrol or 25 µM PD followed by 24 hr posttreatment with 10 µM 4-OHE2 (4-OHE2), or 48 hr treatment with 25 µM resveratrol or 25
µM PD followed by 24 hr post-treatment with 10 µM 4-OHE2 + 25 µM antioxidants (4-OHE2
+ 25 µM R/ PD). Data are presented as mean catechol concentrations from two independent
experiments (n=2).
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Fig. 26. 4-Methoxy conjugate formation in RWPE-1 cells subjected to 48 hr treatment with
25 µM resveratrol or 25 µM PD followed by 24 hr post-treatment growth without any PD or
resveratrol (-), 48 hr treatment with 25 µM resveratrol or 25 µM PD followed by 24 hr posttreatment with 10 µM 4-OHE2 (4-OHE2), or 48 hr treatment with 25 µM resveratrol or 25
µM PD followed by 24 hr post-treatment with 10 µM 4-OHE2 + 25 µM antioxidants (4-OHE2
+ 25 µM R/ PD). Data are presented as mean 4-methoxy conjugate concentrations from two
independent experiments (n=2).
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Fig. 27. Estrogen-3,4-Quinone conjugate formation in RWPE-1 cells subjected to 48 hr
treatment with 25 µM resveratrol or 25 µM PD followed by 24 hr post-treatment growth
without any PD or resveratrol (-), 48 hr treatment with 25 µM resveratrol or 25 µM PD
followed by 24 hr post-treatment with 10 µM 4-OHE2 (4-OHE2), or 48 hr treatment with 25
µM resveratrol or 25 µM PD followed by 24 hr post-treatment with 10 µM 4-OHE2 + 25 µM
antioxidants (4-OHE2 + 25 µM R/ PD). Data are presented as mean 3,4-quinone conjugate
concentrations from two independent experiments (n=2).
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Collectively, both the antioxidants studied did prompt RWPE-1 cells to activate its first
line of defense, NQO1, which lowered adduct formation as well as increased catechol and
conjugate formation. Although PD was found to be less efficacious than resveratrol in inducing the
protective enzyme NQO1 or repressing the activating enzyme CYP1B1 in MCF10A cells, such a
difference was largely non-existent in RWPE-1 cells – rendering PD equally effective as resveratrol
in lowering estrogen-DNA adduct formation. This might be promising, as PD could be a less toxic
alternative for resveratrol in chemo-preventing estrogen-induced cancer initiation in prostate cells.
Future studies with PD in other non-transformed cells might add more generalizability.
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Chapter 3: Estrogen Metabolism in African American Populations
Introduction
Exposure to estrogens has been associated with increased risk of breast (Kaaks et al., 2005)
and ovarian cancer (Hunn and Rodriguez, 2012, Salehi et al., 2008, Sellers et al., 2005). We
previously published three studies showing increased ratios of estrogen-DNA adducts to estrogen
metabolites and conjugates in Caucasian women at high risk for breast cancer or already diagnosed
with the disease (Gaikwad et al., 2008, Gaikwad et al., 2009, Pruthi et al., 2012). We also found
that the ratio of estrogen-DNA adducts to estrogen metabolites and conjugates is elevated in women
diagnosed with ovarian cancer compared to women without ovarian cancer (Zahid et al., 2014).
CYP1B1 is a key activating enzyme in the estrogen metabolic pathway that forms depurinating
estrogen-DNA adducts because it catalyzes the oxidation of E 1 and E2 to the 4-catechol estrogens,
4-OHE1 and 4-OHE2 (Cavalieri and Rogan, 2011). Studies of CYP1B1 polymorphisms and breast
cancer have shown few significant associations, although a meta-analysis found that the Leu432Val
polymorphism selected for this study significantly increased cancer risk (Liu et al., 2015). Studies
of these same polymorphisms in ovarian cancer, however, provide evidence of an association when
examined with other polymorphic enzymes such as COMT. COMT is downstream of CYP1B1
and an important protective enzyme that methylates catechol estrogens, preventing them from
further oxidation to quinones that react with DNA (Fig. 1) (Cavalieri and Rogan, 2011).
Approximately 25% of Caucasians are homozygous for the Val158Met (rs4680, AA)
polymorphism in COMT, resulting in 4- to 5-fold lower activity (Dawling et al., 2001). Women
with two copies of the low-activity SNP for COMT plus two copies of the high-activity SNP
(rs1056836, GG) for CYP1B1 are 6-fold more likely to have ovarian cancer than women with
normal activity alleles (Zahid et al., 2014). In addition, COMT polymorphisms have been
associated with ovarian cancer when combined with other polymorphic enzymes in the catechol
estrogen pathway (Sellers et al., 2005, Delort et al., 2008, Holt et al., 2007).
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To date, no study has examined the consequences in African-American (AA) women of
having a combination of at-risk variants of these genetic polymorphisms in relation to levels of
estrogen metabolites, estrogen conjugates and depurinating estrogen-DNA adducts in breast cancer.
Breast cancer presents somewhat differently in AA women compared to Caucasian women. From
2010-2015 the incidence of breast cancer in AA women was slightly higher in AA women than in
Caucasian women, but mortality was significantly higher in AA women (Alcaraz et al., 2016).
Malignant breast tumors in AA women are more likely to be negative for ER, PR and HER2
(DeSantis et al., 2016). These triple negative tumors are more likely to appear before menopause
in AA women (Dietze et al., 2015). Since breast cancer presents somewhat differently in AA women
compared to Caucasian women, it appeared important to discover whether estrogen metabolism
and formation of depurinating estrogen-DNA adducts is also different. In this pilot study we began
to test the hypotheses that AA women with breast cancer: (1) have a significantly higher ratio of
estrogen-DNA adducts relative to estrogen metabolites and conjugates than AA women without
breast cancer and (2) are more likely to carry a combination of the high activity CYP1B1 allele and
the low activity COMT allele than AA women without breast cancer. A polygenic approach is more
likely to produce a better understanding of the role of metabolic genes on the formation of DNA
adducts and risk of breast cancer.
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Methodology
The study protocol was approved by the Institutional Review Board at the University of
Nebraska Medical Center (UNMC).
Study Population. Urine and saliva samples were collected at one event, the annual Celebration
of Life luncheon sponsored by My Sister’s Keeper, a breast cancer support organization for AA
women in Omaha, NE. Subjects self-identified as having been diagnosed with breast cancer or not
having been diagnosed with breast cancer. Each completed an informed consent form before
collecting a spot urine sample of approximately 50 ml and a saliva sample of approximately 2 ml
in an Oragene tube (Rylander-Rudqvist et al., 2006). Control samples were obtained from 25
women without breast cancer, and 19 women with breast cancer provided urine samples; two of the
control samples could not be analyzed. Among the same women, saliva from all 25 control women
yielded useful DNA, while 17 of the women with breast cancer provided saliva that yielded DNA.
Sample collection. Approximately 50 ml of urine was obtained in a urine specimen cup containing
1mg/ml ascorbic acid (to prevent oxidation of catechol estrogen metabolites). Urine samples were
aliquoted, frozen and stored at -80C until analysis. Thus, each analytical sample was thawed only
once prior to analysis. A saliva sample (~ 2 ml) was collected from each subject in an Oragene
collection tube, which was stored at 3C until purification of DNA (Zahid et al., 2014).
Analysis of estrogen compounds. A 2-ml aliquot of each urine sample was processed and
subjected to UPLC-MS/MS analysis, as discussed in previous chapters. Resulting data were used
to quantify the estrogen metabolites, conjugates and DNA adducts. All the study samples were
analyzed in triplicates in a blinded fashion. The ratio of adducts to their respective metabolites and
conjugates was calculated according to the following formula (Gaikwad et al., 2008):
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The estrogen metabolites include 2-OHE1(E2) and 4-OHE1(E2). The conjugates include 2OCH3E1(E2), 4-OCH3E1(E2), 4-OHE1(E2)-2-SG, 4-OHE1(E2)-2-Cys, and 4-OHE1(E2)-2-NAcCys.
The adducts include 4-OHE1(E2)-1-N3Ade, 4-OHE1(E2)-1-N7Gua, and 2-OHE1(E2)-6-N3Ade.
The ratio was multiplied by 1000 to avoid decimal points and zeroes.
The concentration of each of the compounds and the ratio of depurinating N3Ade and
N7Gua adducts to the sum of their respective estrogen metabolites and conjugates in each urine
sample provides a ratio, which reflects the degree of imbalance in estrogen metabolism that may
lead to cancer initiation (Gaikwad et al., 2008). Mean differences in the DNA adduct ratio were
compared using the t-test.
Sample Collection-SNPs. Oragene collection tubes were used for self-collection of saliva,
stabilization, transportation, storage and genomic DNA purification (Rylander-Rudqvist et al.,
2006). DNA samples were genotyped using TaqMan assays (CYP1B1, C_3099976_30; COMT,
C_25746809_50; ThermoFisher Scientific).
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Results and Discussion
The subjects in this study ranged in age from 41-77 years (median, 56) for controls and
from 43-75 years (median, 65) for cases. The 19 women diagnosed with breast cancer had an
estrogen-DNA adduct ratio (x 1000) of 92.4 ± 46.4, while the 23 women not diagnosed with breast
cancer had a significantly lower ratio of 38.5 ± 18.9 (p < 0.001, Fig. 28). These results are similar
to those observed previously with Caucasian women (Gaikwad et al., 2008, Gaikwad et al., 2009,
Pruthi et al., 2012). In the previous studies, the ratio was significantly higher in both women with
breast cancer and those at high risk for the disease, suggesting that formation of depurinating
estrogen-DNA adducts plays a role in the initiation of breast cancer. In this first set of samples from
AA women, we did not know whether control women were at normal or high risk for breast cancer.
Nonetheless, AA women with breast cancer appear to metabolize estrogens and form depurinating
estrogen-DNA adducts similarly to Caucasian women.
Despite the small number of participants, we also collected saliva for isolation of genomic
DNA and genotyped CYP1B1 (Val432Leu, rs1056836), an estrogen activating enzyme, and COMT
(Val158Met, rs4680), an estrogen protective enzyme (Fig. 1). The two polymorphisms were in
Hardy-Weinberg equilibrium in the study population (CYP1B1: χ2 = 2.58, p = 0.11; COMT: χ2 =
0.58, p = 0.45). Allele frequencies for these two SNPs are similar to that reported in dbSNP for AAs
(Table 1). We did not see an association of CYP1B1 (Val432Leu, rs1056836) and COMT
(Val158Met, rs4680) SNPs with the ratio of DNA adducts or breast cancer. Using a polygenic
approach with possible genotype combinations between COMT and CYP1B1, we also did not see
any significant associations with DNA adduct ratios (p = 0.54) or breast cancer (p = 0.81). In larger
studies, the CYP1B1 Val432Leu SNP, which increases its activity, was associated with breast
cancer in AA women (Kato et al., 2009, Haddad et al., 2015). One possible confounder is that AA
women have been reported to have lower frequencies of the COMT Val158Met SNP than Caucasian
women (Beuten et al., 2006).
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Fig. 28. Mean ratio and standard deviation of urinary depurinating estrogen-DNA adducts to
estrogen metabolites and conjugates for AA women diagnosed with breast cancer (cases) or
not diagnosed with cancer (controls) (Zahid et al., 2018).
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Table 1. Association of CYP1B1 and COMT polymorphisms with DNA adduct ratios and
breast cancer (Zahid et al., 2018).
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Although the number of subjects was too small to obtain useful information about CYP1B1
and COMT activity in estrogen metabolism in these women, the estrogen-DNA adducts ratios in
the breast cancer cases and controls were similar to those previously observed in Caucasian women
(Gaikwad et al., 2008, Gaikwad et al., 2009, Pruthi et al., 2012). These results are consistent with
the hypothesis that formation of estrogen-DNA adducts may be a critical factor in the etiology of
breast cancer in AA women. A larger, more comprehensive study of estrogen metabolism and DNA
adduct formation in AA women is warranted.
A similar pilot study, albeit with even smaller sample size, was performed for AA men
diagnosed with prostate cancer, at high risk (HR) but not diagnosed with cancer, and not diagnosed
with cancer (control). As shown in the Fig. 29 inset, the mean ratio for the control group (26.6 ±
63.4) was lower than the same for the HR group (43.3 ± 29) and the cancer group (80.3 ± 48.3).
However, the extremely small sample sizes for the HR and cancer groups make the standard
deviations unusable, and certainly call for a larger study to achieve any statistical significance.
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Fig. 29. Ratios of urinary depurinating estrogen-DNA adducts to estrogen metabolites and
conjugates for individual AA men diagnosed with prostate cancer (solid black), at high risk
but not diagnosed with cancer (HR; patterned black), and not diagnosed with cancer (solid
grey). Inset: Mean ratios and standard deviations for each group (Zahid et al., 2018).
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Taken together, these pilot studies indicated AA women with breast cancer, and AA men at
high risk for or with prostate cancer might have higher estrogen-DNA adduct ratios than the
controls; and the lack of statistical significance in the study with men suffers from extremely small
sample sizes. This suggests that estrogen metabolism might be out of balance, and the formation of
estrogen-DNA adducts may exert a critical role in breast cancer initiation in AA populations –
which is in accordance with our earlier observations in Caucasian populations. However, no
associations between the CYP1B1 and COMT genotypes studied and adduct ratios for breast cancer
were observed in AA women. This needs to be studied in a much larger population of women.
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Chapter 4: Estrogen Metabolism in FECD
Introduction
Way back in 1910, Ernst Fuchs first reported a debilitating disorder of the posterior cornea,
which was subsequently referred to as Fuch’s Corneal Dystrophy (FCD). Early research indicated
FCD only affects corneal endothelium, or human corneal endothelial cells (HcEnCs), hence the
name was changed to FECD (Vogt, 1921). Although the clinical symptoms of FECD vary, there
are certain salient features: the characteristic blurry morning vision is reported by patients mostly
in their fifth and sixth decades of life, it’s slow-progressing (Friedenwald et al., 1925), bilaterally
symmetrical, and sex-linked, with women 2-4 times more susceptible than men (Wilson et al,
1988). In the US, approximately 4 percent of people over the age of 40 suffer from late-onset FECD,
and it is currently the leading cause of corneal transplantation surgeries in the U.S. and developed
world (Gain et al., 2016).
In healthy eyes, post-mitotically arrested hexagonal HcEnCs sit on the basement membrane
of the cornea (Descemet’s membrane) and maintain the clarity of corneal stroma. The central
cornea receives more UV light than the peripheral parts, and FECD has been reported to start with
the central cornea, which then spreads peripherally (Doutch et al., 2012). Exposure to UV and
concomitant oxidative stress have been implicated in DNA damage and induction of endothelialto-mesenchymal transition (EMT) in HcEnCs – which leads to thickening of Descemet’s
membrane, extracellular matrix deposition in the form of pro-fibrotic focal outgrowths called
guttae, corneal edema, and eventual loss of vision (Fig. 3).
Although the present literature lacks any explanation for the skewed gender ratio for FECD
prevalence, a role for sex hormones has been postulated. Interestingly, UV exposure can
differentially induce the key enzymes involved in estrogen metabolism (Katiyar et al., 2000),
whereas the main protecting enzyme involved in estrogen metabolism, NQO1, has also been shown
to prevent EMT. In a menadione (MN)-induced oxidative stress model in HcEnCs, our collaborator
Dr. Ula Jurkunas at Harvard Medical School, Boston, MA, United States, has observed MN to
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induce DNA damage, upregulation of EMT markers, and rosette formations characteristic to FECD
(Katikireddy et al., 2018). MN is metabolized to menadiol by NQO1. On the other hand, NQO1
has been reported to be repressed in both FECD and in MN-treatment (Fig. 30). To recapitulate
FECD, the same study also used NQO1 KO cells where a heightened cytotoxicity to MN and
apoptosis were observed. A quest to identify novel chemotherapeutic preventions for FECD has
shown promising results with ROS-quencher NAC and NQO1-inducer sulforaphane, both of which
have been shown to lessen oxidative stress and inhibit EMT. Present literature as well as previous
chapters strongly implicate the role of a disbalanced estrogen metabolism in DNA-damage and
cancer initiation, which could also be prevented to some extent by NAC (Cavalieri and Rogan,
2016) and NQO1 inducers. Considering such striking parallels, exploring estrogen metabolism
balance in FECD and correction of any said disbalance with naturally occurring compounds might
provide molecular insights into FECD etiology and might potentiate the use of chemotherapeutic
agents like NAC.
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Fig. 30. Repression of NQO1 by menadione in HCEnC-21T cells. (A) Representative gel
image. (B) Quantitative data. Data are presented as mean ± standard error of the mean protein
expression from three independent experiments (n=3), with control taken as unit. A * indicates a
significant difference (p < 0.05) whereas a *** indicates a highly significant difference (p < 0.001)
between the means of 2 groups (Katikireddy et al., 2018).
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Methodology
Generation of NQO1+/+ and NQO1 KO Cells (at Harvard): To abrogate the expression of
NQO1 in HCEnC-21T cells, the NQO1 locus was targeted for a Crispr-Cas9 mediated excision by
transfection of 2 μg of either NQO1 Double Nickase plasmid (sc-400326-NIC, Santa Cruz) or
Control Double Nickase plasmid (sc-437281, Santa Cruz) in low passage HCEnC-21T cells.
Analysis of Estrogen-Metabolism: NQO1+/+ and NQO1 KO HCEnC-21T cells were seeded in
T75 flasks (seeding density: 1X106 cells per T75 flask, 4 flasks per treatment). Following
attachment, cells were pre-treated with estrogen- and phenol red indicator-free media for 48 hrs,
and treatment was given with 8.5 μM MN or 3.75 μM 4-OHE2 or 8.5 μM MN + 3.75 μM 4-OHE2
or 8.5 μM MN + 3.75 μM 4-OHE2 + 25 μM NAC for 24 hrs (MN, 4-OHE2, and MN + 4-OHE2
treatment concentrations were optimized following cell viability assays summarized in Fig. 31).
The bathing media were pooled for every treatment and collected media was analyzed by UPLCMS/MS (at UNMC) as described in the previous chapters for: 1. Depurinating estrogen-DNA
adducts, 4-OHE1(E2)-1-N3Ade and 4-OHE1(E2)-1-N7Gua, 2. 4-catechol estrogen metabolites 4OHE1(E2), 3. 4-catechol estrogen methoxy conjugates 4-OCH3E1(E2), and 4. 4-catechol estrogen
quinone conjugates 4-OHE1(E2)-2-SG, 4-OHE1(E2)-2-Cys, and 4-OHE1(E2)-2-NAcCys.
Statistical Analysis: To determine whether the differences observed were statistically significant
or not, a 2-sample t-test was performed. Alpha was set at 0.05 for all statistical tests and data with
p < 0.05 were considered to be significantly different.
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Fig. 31. Viability of HCEnC-21T cells treated with (A) MN. (B) 4-OHE2. (C) MN + 4-OHE2.
Data are presented as mean ± standard error of the mean cell survival (%) from six independent
experiments (n=6) (Unpublished data, Dr. Ula Jurkunas lab at Harvard Medical School, Boston,
MA).
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Results and Discussion
The levels of 14 estrogen metabolites including catechol estrogens, estrogen conjugates
and DNA-adducts from wild type and NQO1 KO HCEnC-21T cells subjected to metabolic assay
were analyzed. The data shows that MN co-treatment increased adduct [sum of 4-OHE1(E2)-1N3Ade and 4-OHE1(E2)-1-N7Gua] formation (Fig. 32) while lowering 4-methoxy conjugate
formation (Fig. 33). As MN represses NQO1, this might lead to a surplus of non-neutralized
quinones, which might lead to the formation of more DNA-adducts. Less formation of 4-methoxy
conjugates would stem from the same lower NQO1 expression. However, MN co-treatment did not
cause much difference in estrogen-3,4-quinone conjugate formation (Fig. 34).
Next, effects of both MN and NAC treatment were studied in the presence and absence of
any functional NQO1 enzyme. In agreement with our findings discussed in the previous paragraph,
MN did increase adduct [sum of 4-OHE1(E2)-1-N3Ade and 4-OHE1(E2)-1-N7Gua] formation (Fig.
35) while lowering 4-methoxy conjugate formation (Fig. 36) in NQO1 wild type cells. In the same
cells, co-treatment with MN and NAC lowered adduct formation (Fig. 35) with a concomitant
increase in estrogen-3,4-quinone conjugate formation (Fig. 37). Interestingly, co-treatment of
NQO1 wild type cells with MN and NAC further lowered 4-methoxy conjugate formation (Fig.
35). NQO KO cells roughly followed the same trends (Figs. 35-37).
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Fig. 32. Depurinating adduct formation in HCEnC-21T cells subjected to 24 hr treatment
with 3.75 μM 4-OHE2 or 8.5 μM menadione + 3.75 μM 4-OHE2. Data are presented as mean ±
standard error of the mean adduct (4-OHE1/2-1-N7Gua + 4-OHE1/2-1-N3Ade) concentrations from
five independent experiments (n=5).
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Fig. 33. 4-Methoxy conjugate formation in HCEnC-21T cells subjected to 24 hr treatment
with 3.75 μM 4-OHE2 or 8.5 μM menadione + 3.75 μM 4-OHE2. Data are presented as mean ±
standard error of the mean 4-methoxy conjugate concentrations from five independent experiments
(n=5).
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Fig. 34. Estrogen-3,4-Quinone conjugate formation in HCEnC-21T cells subjected to 24 hr
treatment with 3.75 μM 4-OHE2 or 8.5 μM menadione + 3.75 μM 4-OHE2. Data are presented
as mean ± standard error of the mean 3,4-quinone conjugate concentrations from five independent
experiments (n=5).
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Fig. 35. Depurinating adduct formation in wild type (NQO1 +/+) and NQO1 knock out
(NQO1 -/-) HCEnC-21T cells subjected to 24 hr treatment with 3.75 μM 4-OHE2 or 8.5 μM
menadione + 3.75 μM 4-OHE2 or 8.5 μM menadione + 3.75 μM 4-OHE2 + 25 μM NAC. Data
are presented as mean ± standard error of the mean adduct (4-OHE1/2-1-N7Gua + 4-OHE1/2-1N3Ade) concentrations from six independent experiments (n=6).

74

Fig. 36. 4-Methoxy conjugate formation in wild type (NQO1 +/+) and NQO1 knock out
(NQO1 -/-) HCEnC-21T cells subjected to 24 hr treatment with 3.75 μM 4-OHE2 or 8.5 μM
menadione + 3.75 μM 4-OHE2 or 8.5 μM menadione + 3.75 μM 4-OHE2 + 25 μM NAC. Data
are presented as mean ± standard error of the mean 4-Methoxy conjugate concentrations from six
independent experiments (n=6).
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Fig. 37. Estrogen-3,4-Quinone conjugate formation in wild type (NQO1 +/+) and NQO1
knock out (NQO1 -/-) HCEnC-21T cells subjected to 24 hr treatment with 3.75 μM 4-OHE2
or 8.5 μM menadione + 3.75 μM 4-OHE2 or 8.5 μM menadione + 3.75 μM 4-OHE2 + 25 μM
NAC. Data are presented as mean ± standard error of the mean 3,4-Quinone conjugate
concentrations from six independent experiments (n=6).
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Taken together, this suggests that NAC might be helpful in ameliorating MN-induced DNA
damage. This is particularly important in NQO1 KO cells as these cells represent a better model
for FECD. Such observations, coupled with the ability of NAC to prevent EMT, make NAC a very
promising therapeutic modality for FECD. However, this needs to be supported with in vivo modelbased studies. Also, it would be interesting to explore whether NQO1-inducers like sulforaphane
or resveratrol can provide any restoration from MN-induced estrogen metabolism disbalance, what
the degree of such protection (if any) is, and if these compounds can be used synergistically with
NAC for a better treatment of FECD.
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Conclusions
In order to explain the receptor-independent pathway of cancer initiation by estrogens, our
laboratory formulated the central hypothesis that metabolism of endogenous or environmental
estrogens/androgens generates catechol quinones that can react with DNA, leading to the formation
of apurinic sites, which in turn generate mutations, and initiate oncogenic transformation. Over the
past decade, numerous types of in vitro and in vivo evidence have established a link between
estrogen genotoxicity and carcinogenesis. However, these studies were either only mono-racial, or
the restoration of the dynamic balance in estrogen metabolism using naturally occurring
compounds were not very useful for human trials. At the same time, recent studies have also
implicated estrogen metabolism in non-cancerous pathologies like FECD. Therefore, to move
forward towards prevention of pathologies, the role of estrogen metabolism in FECD, in cancer
initiation in AA populations, and its modulation by environmental toxicants, As2O3, and the
naturally occurring antioxidants PD and resveratrol were explored.
In accordance with the existing literature, As2O3 was observed to induce cytotoxicity in
human breast epithelial non-transformed MCF10A cells, which was partially ameliorated by 25
μM resveratrol. The oxidative insult of cells by As2O3 did prompt cells to activate their first line of
defense, NQO1, via Nrf2 stabilization; and both these effects were also shared by 25 μM
resveratrol. Interestingly, As2O3 suppressed CYP1B1 expression whereas 25 μM resveratrol
restored it to basal levels -- rendering the As2O3 + resveratrol combination a little less effective than
As2O3 alone in lowering estrogen-DNA adduct formation. Based on these observations, we cannot
conclude that resveratrol co-treatment with As 2O3 has any beneficial roles on estrogen metabolism.
However, resveratrol might be beneficial owing to its chemical properties as well as the protection
from As2O3-cytotoxicity might stem from other cellular pathways.
The comparative study between two naturally occurring antioxidants PD and resveratrol
found PD to be safer than resveratrol. Both the compounds induced NQO1, albeit in varying
degrees, leading to lowering of adduct formation. In human breast epithelial non-transformed
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MCF10A cells, PD was found to be less efficacious than resveratrol in inducing the protective
enzyme NQO1 or repressing the activating enzyme CYP1B1, although such a difference was
largely non-existent in human prostate epithelial non-transformed RWPE-1 cells – rendering both
the antioxidants equally effective in lowering estrogen-DNA adduct formation. This indicates that
PD could be a less toxic alternative for resveratrol in chemo-preventing estrogen-induced cancer
initiation in prostate cells.
Epidemiological studies indicated AA women with breast cancer do have higher estrogenDNA adduct ratios than the controls, whereas AA men at high risk for or with prostate cancer might
have higher estrogen-DNA adduct ratios than the controls. This suggests loss of the balance in
estrogen metabolism might be instrumental in breast and prostate cancer initiation in AA
populations – which is in accordance with our earlier observations in Caucasian populations.
However, no associations between CYP1B1 and COMT genotypes studied and adduct ratios for
breast cancer were observed in AA women. This calls for larger study populations and/ or a shift in
the genetic polymorphisms studied.
Based on the studies in the MN-induced in vitro FECD model, it was observed NAC might
be helpful in ameliorating estrogen-DNA adduct formation. The finding that such protection from
NAC happens even in absence of any functional NQO1 makes it an even more promising
therapeutic modality for FECD, as NQO1 KO cells represent a better model for FECD. In vivo
model-based evidence can potentiate such claims, whereas exploration of similar chemopreventive
effects of NQO1-inducers like sulforaphane or resveratrol can lead to even better treatments for
FECD.
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